Suppr超能文献

非瓣膜性心房颤动患者在初级保健水平应用利伐沙班治疗:瑞士心房颤动抗凝治疗研究(STAR)。

Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.

机构信息

Division of Angiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Clinic for Angiology, Swiss Cardiovascular Center, Inselspital, University Hospital and University of Bern, Switzerland.

HerzKlinik, Klinik Hirslanden, Zürich, Switzerland.

出版信息

Eur J Intern Med. 2015 Sep;26(7):508-14. doi: 10.1016/j.ejim.2015.04.014. Epub 2015 Apr 30.

Abstract

BACKGROUND

Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known.

METHODS

Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up.

RESULTS

We enrolled 537 patients (73±11years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2±1.3 and 2.4±1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naïve (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6±1.4 under VKA to 5.5±0.8 points (P<0.001), and overall physician satisfaction from 3.9±1.3 to 5.4±0.9 points (P<0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4±0.9) and physician's satisfaction (5.5±0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95%CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95%CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95%CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason.

CONCLUSION

Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction.

摘要

背景

在非瓣膜性心房颤动(AF)患者中,利伐沙班因其在大型随机试验的限制条件下具有良好的风险效益比,已成为维生素 K 拮抗剂(VKA)的替代药物,用于预防中风。然而,在初级保健环境中,医生开始使用利伐沙班的动机、治疗满意度以及开始使用利伐沙班后的临床事件发生率尚不清楚。

方法

瑞士 115 名初级保健医生对新接受利伐沙班抗凝治疗的非瓣膜性 AF 连续患者进行前瞻性数据收集,并进行 3 个月的随访。

结果

我们纳入了 537 名患者(73±11 岁,57%为男性),平均 CHADS2 和 HAS-BLED 评分分别为 2.2±1.3 和 2.4±1.1:301 名(56%)患者从 VKA 转为利伐沙班(STR 组),236 名(44%)为 VKA 初治(VN 组)。不常规进行凝血监测(68%)和固定剂量每日一次治疗(58%)是医生开始使用利伐沙班的最常见标准。在 STR 组中,患者的满意度从 VKA 下的 3.6±1.4 分增加到 5.5±0.8 分(P<0.001),整体医生满意度从 3.9±1.3 分增加到 5.4±0.9 分(P<0.001)在接受利伐沙班治疗 3 个月时(得分从 1 到 6,得分越高表示满意度越高)。在 VN 组中,随访时患者(5.4±0.9)和医生(5.5±0.7)的满意度与 STR 组相当。随访期间,发生 1 例(0.19%;95%CI,0.01-1.03%)缺血性中风、2 例(0.37%;95%CI,0.05-1.34%)主要非致命性出血和 11 例(2.05%;95%CI,1.03-3.64%)轻微出血并发症。30 名(5.6%)患者停止使用利伐沙班,副作用是最常见的原因。

结论

初级保健医生为非瓣膜性心房颤动患者启动利伐沙班治疗与较低的临床事件发生率和较高的总体患者和医生满意度相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验